Cutibacterium acnes proteins and cellular components (C. acnes components)

Cutibacterium acnes (formerly Propionibacterium acnes) is a Gram-positive, anaerobic bacterium that is a key component of the human skin microbiome, particularly within the pilosebaceous unit (StatPearls: Acne Vulgaris). The proteins and cellular components of C. acnes, including secreted lipases, proteases, and Christie-Atkins-Munch-Petersen (CAMP) factors, are critical mediators of inflammation and tissue damage in acne vulgaris (Brüggemann et al., 2004, Science). Lipases such as GehA break down sebum into free fatty acids, which irritate the follicular epithelium and recruit immune cells (Miskin et al., 1997, Microbiology). Cellular components like peptidoglycan and lipoteichoic acid act as pathogen-associated molecular patterns (PAMPs) that activate Toll-like receptor 2 (TLR2) on keratinocytes and macrophages, triggering the production of pro-inflammatory cytokines like IL-1β and IL-8 (Kim et al., 2002, Journal of Immunology). Therapeutic interventions targeting these components range from broad-spectrum antibiotics that inhibit bacterial protein synthesis to targeted vaccines currently in development that aim to neutralize specific virulence factors like CAMP factor 2 or sialidase (Nakatsuji et al., 2008, Journal of Investigative Dermatology). Managing C. acnes is essential for treating inflammatory acne, though increasing antibiotic resistance remains a significant clinical challenge (Walsh et al., 2016, Dermatology and Therapy).

Other names

Propionibacterium acnesP. acnesAcne bacillusC. acnes antigens

Antibiotics like clindamycin and erythromycin bind to the 50S ribosomal subunit, while tetracyclines bind to the 30S subunit, both inhibiting bacterial protein synthesis (StatPearls: Antibiotics). Benzoyl peroxide acts as an oxidizing agent, releasing free radical oxygen species that bacterially kill C. acnes by damaging membranes and DNA (PubChem). Experimental vaccines and monoclonal antibodies target specific secreted proteins like CAMP factor 2 or sialidase to neutralize their pro-inflammatory and cytotoxic effects (Nakatsuji et al., 2008).